Diabetics in New Zealand are welcoming a Pharmac decision to fund long-acting insulin, that has been available abroad for years.
The government agency that purchases drugs announced yesterday that it would fund the insulin, glargine, from July 1. It is also known by its trade name, Lantus.
Wayne McNee, Pharmac chief executive, said the drug, which was priced at $5 million, reduces the risk of hypo glycaemia which could lead to muscle weakness, confusion and sweating, and in the worst cases, to coma.
Complications of un-controlled diabetes include problems of the eye, kidney and heart.